ERCC1基因多态性与晚期胃癌患者奥沙利铂化疗疗效的相关性研究  

Study on the relationship between ERCC1 gene polymorphism and the efficacy of oxaliplatin in patients with advanced gastric cancer

作　　者：张倩[1] 汤旭山[2] 朱雅婷[1] 周湘龙[1] ZHANG Qian;TANG Xu-shan;ZHU Ya-ting;ZHOU Xiang-long(Department of Pharmacy,Tumor Hospital Affiliated to Xinjiang Medical University,Urumqi 830011,China;Department of Gastroenterology,Tumor Hospital Affiliated to Xinjiang Medical University,Urumqi 830011,China)

机构地区：[1]新疆医科大学附属肿瘤医院药学部,新疆乌鲁木齐830011 [2]新疆医科大学附属肿瘤医院消化内科,新疆乌鲁木齐830011

出　　处：《中国药物应用与监测》2020年第5期295-298,共4页Chinese Journal of Drug Application and Monitoring

基　　金：新疆维吾尔自治区自然科学基金项目(2017D01C404)。

摘　　要：目的:探讨切除修复交叉互补基因1(ERCC1)基因多态性与与晚期胃癌患者奥沙利铂化疗疗效的相关性。方法:采用前瞻性的研究方法,选取采用奥沙利铂联合替吉奥方案(SOX)化疗的晚期胃癌患者60例,提取外周血DNA,采用限制性片段长度多态性聚合酶链反应(PCR-RFLP)技术检测ERCC1118C/T位点基因型,分析ERCC1基因多态性与SOX方案化疗的有效率及无进展生存期的关系。结果:60例胃癌患者的ERCC1118C/T位点存在3种等位基因型,其基因频率分别为C/C 32例(53.3%),C/T 24例(40.0%),T/T 4例(6.7%),其中C/C型患者化疗有效率(40.6%)较C/T+T/T型患者有效率稍高(35.7%),C/C型患者的平均无进展生存期(PFS)为8.49个月,C/T+T/T型平均PFS为10.44个月,但不同基因型之间差异无统计学意义(P>0.05)。结论:ERCCl 118C/T基因多态性与SOX方案化疗的疗效无关。Objective:To investigate the correlation between excision repair cross-complementation 1(ERCC1)gene polymorphism and the efficacy of oxaliplatin in patients with advanced gastric cancer.Methods:Prospective research methods were used,the peripheral blood DNA was extracted from 60 patients with advanced gastric cancer who received oxaliplatin combined with tegafur(SOX)chemotherapy regimen.The genotype of ERCC1118 C/T was detected by polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP)method to explore the relationship between ERCC1 gene polymorphism and the efficacy and progression-free survival time(PFS)of SOX chemotherapy regimen.Results:There were three allelotypes at the 118 C/T locus of ERCC1 in 60 patients with gastric cancer,among which C/C types was 32 cases(53.3%),C/T types was 24 cases(40.0%)and T/T types was 4 cases(6.7%).The effective rate of SOX chemotherapy regimen in patients with C/C type was 40.6%,which was slightly higher than that of patients with C/T and T/T type(35.7%).The average PFS of C/C patients and(C/T+T/T)patients was 8.49 months and 10.44 months respectively,but there was no significant difference among patients with different genotypes(P>0.05).Conclusion:ERCCl 118 C/T polymorphism was not related to the efficacy of SOX chemotherapy regimen.

关 键 词：切除修复交叉互补基因1 基因多态性 胃癌 奥沙利铂 疗效 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]